Amivantamab or Cetuximab for Skin Cancer in People with Weakened Immune Systems
Treatments studied
Part of Cancer, Immune system & allergy, Skin clinical trials.
This trial tests two drugs, amivantamab with hyaluronidase or cetuximab, in people with weakened immune systems who have advanced skin cancer (squamous cell carcinoma). The goal is to see if these treatments can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of skin cancer called cutaneous squamous cell carcinoma that has spread or come back.
- Your immune system must be weakened due to a blood cancer, organ transplant, autoimmune disease treated with strong medications, or similar condition.
- You must not have received cetuximab or another EGFR inhibitor drug in the past year.
- Your recent blood tests and heart function must meet certain safety levels (your doctor can check this).
- You must be at least 18 years old and have a performance status of 0-2 (able to do daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
This trial tests a new drug (amivantamab) combined with two chemotherapy drugs (carboplatin and paclitaxel) for people with head and neck cancer that has spread or come back after treatment and cannot be removed by surgery. This study aims to see if this combination can help shrink tumors.
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
This study tests a new drug called amivantamab for penile cancer that has spread and hasn't responded to earlier treatments. The drug may block signals that help cancer grow. The study also looks at how the HPV virus affects treatment response.
This trial tests a combination of two targeted drugs (an immunotherapy and an EGFR inhibitor) given before surgery to shrink locally advanced skin cancer and potentially make surgery easier or more successful. It may help people whose skin cancer is hard to treat with surgery alone.
Hear when a new Metastatic Skin Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.